QURE Latest Headlines

Analysts Offer Insights on Healthcare Companies: uniQure (QURE) and Tenax Therapeutics (TENX)

at www.tipranks.com (Thu, 30-Jul 1:40 PM)

Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE)

at www.tipranks.com (Thu, 30-Jul 1:20 PM)

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Fortrea Holdings Inc. (FTRE) and uniQure (QURE)

at www.tipranks.com (Thu, 30-Jul 8:40 AM)

RBC Capital Sticks to Their Buy Rating for uniQure (QURE)

at www.tipranks.com (Thu, 30-Jul 7:07 AM)

Barclays Keeps Their Buy Rating on uniQure (QURE)

at www.tipranks.com (Thu, 30-Jul 5:17 AM)

uniQure’s Strong Cash Position Supports Accelerated Pipeline Progress Heading Into AMT-130 Regulatory Milestones

Market Chameleon (Wed, 29-Jul 7:59 AM)

Analysts Are Bullish on Top Healthcare Stocks: AbCellera Biologics (ABCL), uniQure (QURE)

at www.tipranks.com (Wed, 29-Jul 4:50 PM)

uniQure GAAP EPS of -$1.22 misses by $0.42, revenue of $5.84M beats by $0.46M

at seekingalpha.com (Wed, 29-Jul 7:18 AM)

Here are the major earnings before the open Wednesday

at seekingalpha.com (Tue, 28-Jul 6:00 PM)

uniQure Q2 2026 Earnings Preview

at seekingalpha.com (Tue, 28-Jul 10:24 AM)

uniQure Raises $259 Million in Upsized Public Offering to Fuel Gene Therapy Pipeline Expansion

Market Chameleon (Fri, 26-Jun 9:21 AM)

uniQure Raises $225 Million in Upsized Public Offering—Key Takeaways and Strategic Implications for Investors

Market Chameleon (Wed, 24-Jun 8:10 AM)

FDA Signals Path for uniQure’s Huntington’s Therapy: Accelerated Approval on the Horizon for AMT-130

Market Chameleon (Wed, 17-Jun 10:29 AM)

FDA Signals Path Forward for uniQure’s AMT-130: Accelerated Approval in Huntington’s Disease Set for 2026 Submission

Market Chameleon (Wed, 17-Jun 8:12 AM)

uniQure Sets Sights on AMT-130 Marketing Authorization in UK After Positive MHRA Feedback

Market Chameleon (Thu, 30-Apr 7:36 AM)